Skip to main content

ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.

Publication ,  Journal Article
Subramaniam, RM; Bradshaw, ML; Lewis, K; Pinho, D; Shah, C; Walker, RC
Published in: Clin Nucl Med
December 2018

Radiopharmaceuticals targeting cell surface expression of somatostatin receptors (SSTRs) are particularly useful in the evaluation of neuroendocrine tumors. Gallium-68 DOTA-Tyr-octreotatate (Ga-DOTATATE) primarily binds to SSTR type 2 receptors. Ga DOTATATE PET/CT is proven to have high impact on the management of neuroendocrine patients compared to traditional anatomical imaging as well as provides additional information over that of conventional nuclear medicine studies (indium-III DTPA-octreotide). It can result in change in management of approximately 75% of patients with neuroendocrine tumors. Ga DOTATATE and F FDG PET/CT imaging are complementary, with the degree of uptake varying depending on the degree of differentiation of the tumor. Well-differentiated tumors maintain their SSTRs and are positive on Ga DOTATATE PET/CT scan, while dedifferentiated tumors are less likely to demonstrate uptake of Ga DOTATATE but will demonstrate uptake with F FDG PET/CT. In addition, Ga DOTATATE PET/CT identifies patients with SSTR expression in their tumors, who have progressed on somatostatin analog therapy, for treatment with Lu DOTATATE.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Nucl Med

DOI

EISSN

1536-0229

Publication Date

December 2018

Volume

43

Issue

12

Start / End Page

899 / 908

Location

United States

Related Subject Headings

  • Societies, Medical
  • Radiopharmaceuticals
  • Radiology
  • Practice Guidelines as Topic
  • Positron Emission Tomography Computed Tomography
  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Neuroendocrine Tumors
  • Humans
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Subramaniam, R. M., Bradshaw, M. L., Lewis, K., Pinho, D., Shah, C., & Walker, R. C. (2018). ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors. Clin Nucl Med, 43(12), 899–908. https://doi.org/10.1097/RLU.0000000000002309
Subramaniam, Rathan M., Marques L. Bradshaw, Kenneth Lewis, Daniella Pinho, Chirayu Shah, and Ronald C. Walker. “ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.Clin Nucl Med 43, no. 12 (December 2018): 899–908. https://doi.org/10.1097/RLU.0000000000002309.
Subramaniam RM, Bradshaw ML, Lewis K, Pinho D, Shah C, Walker RC. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors. Clin Nucl Med. 2018 Dec;43(12):899–908.
Subramaniam, Rathan M., et al. “ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors.Clin Nucl Med, vol. 43, no. 12, Dec. 2018, pp. 899–908. Pubmed, doi:10.1097/RLU.0000000000002309.
Subramaniam RM, Bradshaw ML, Lewis K, Pinho D, Shah C, Walker RC. ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors. Clin Nucl Med. 2018 Dec;43(12):899–908.

Published In

Clin Nucl Med

DOI

EISSN

1536-0229

Publication Date

December 2018

Volume

43

Issue

12

Start / End Page

899 / 908

Location

United States

Related Subject Headings

  • Societies, Medical
  • Radiopharmaceuticals
  • Radiology
  • Practice Guidelines as Topic
  • Positron Emission Tomography Computed Tomography
  • Organometallic Compounds
  • Nuclear Medicine & Medical Imaging
  • Neuroendocrine Tumors
  • Humans
  • 3202 Clinical sciences